Towards a Next-Generation Sequencing Diagnostic Service for Tumour Genotyping: A Comparison of Panels and Platforms

Table 1

Mutation status of the 8 bladder cancer cell lines.

Cell line	BRAF (NM_004333.4)	FGFR3 (NM_00142.4)	KRAS (NM_033360.2)	NRAS (NM_002524.3)	PIK3CA (NM_006218.2)	TP53 (NM_000546.5)
639V		c.742C>T			c.3197C>T	c.743G>A
92-1						c.472C>T, c.670G>A, c.682G>C, c.839G>C, c.880G>A
97-7		c.746C>G				c.120G>A, c.221_236del16
J82		c.1948A>G				c.811G>A, c.960G>C
JO’N			c.38G>A			c.853G>A
KU-19-19				c.182A>G
LUCC3	c.1786G>C				c.1633G>A	c.840_841insAA
UM-UC3			c.34G>T			c.338T>G